Peripheral Blood Biomarkers in Idiopathic Interstitial Pneumonias
|Idiopathic Interstitial Pneumonias|
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
|Official Title:||Genetics, Genomics, and Proteomics of Idiopathic Interstitial Pneumonias: Identification of Susceptibility Genes, Biomarkers, and Molecular Phenotyping|
Tubes of blood will be drawn from the subject to extract RNA and DNA for laboratory purposes.
Lung biopsy tissue (pathology slides) may be requested for specimen processing.
Also Bronchoscopy fluid may be requested.
|Study Start Date:||April 2010|
|Study Completion Date:||February 2013|
|Primary Completion Date:||February 2013 (Final data collection date for primary outcome measure)|
Sporadic (idiopathic) or familial interstitial pneumonia
We are recruiting patients with Idiopathic Pulmonary Fibrosis and other types of Idiopathic Interstitial Pneumonias that occur sporadically or familial (2 or more affected individuals in a family). Participation can be done by mail or visiting Duke University Medical Center (Durham, NC)or National Jewish Health (Denver, CO).
The Broad Challenge Area addressed in this proposal is (03) Biomarker Discovery and Validation, and the Specific Challenge Topic is 03-HL-101 (Identify and validate clinically relevant, quantifiable biomarkers of diagnostic and therapeutic responses for blood, vascular, cardiac, and respiratory tract dysfunction). Idiopathic interstitial pneumonia (IIP) is a lung disease(s) that primarily affects the elderly, but is present in all age groups. IIP causes respiratory insufficiency and is often fatal. In about half of the patients, the diagnosis requires an invasive lung biopsy which can cause complications, and is not always accurate.
The current diagnostic tools for IIP are inadequate. In addition to inaccurate diagnosis, they are very costly, and often result in delayed diagnosis and treatment. The challenge(s) we intend to address in this proposal is to improve the accurate and early diagnosis of idiopathic interstitial lung pneumonia (IIP), and to improve the ability to differentiate the subtypes of idiopathic interstitial pneumonias (IIPs) by developing peripheral blood biomarkers.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01151527
|United States, Colorado|
|National Jewish Health|
|Denver, Colorado, United States, 80206|
|United States, North Carolina|
|Duke University Medical Center|
|Durham, North Carolina, United States, 27710|
|Principal Investigator:||Mark P Steele, MD||Duke University|
|Principal Investigator:||David A Schwartz, MD||National Jewish Health|